Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study Assessing the Feasibility and Clinical Efficacy of Adaptive Immunotherapy Combination With VEGFR-TKI in Patients With Advanced Renal Cell Carcinoma

NCT06860386 is registered in ClinicalTrials.gov with H. Lee Moffitt Cancer Center and Research Institute as lead sponsor.

NCT NCT06860386
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06860386 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study Assessing the Feasibility and Clinical Efficacy of Adaptive Immunotherapy Combination With VEGFR-TKI in Patients With Advanced Renal Cell Carcinoma
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Phase
Phase 2
Overall status
Suspended
Start date
February 25, 2025
Completion date
February 29, 2028
Enrollment
75 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

clear cell renal cell carcinoma, renal cell carcinoma